Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. uri icon

abstract

  • BACKGROUND: A 31-gene genetic expression profile (31-GEP; Class 1=low risk, Class 2=high risk) developed to predict outcome in cutaneous melanoma (CM) has been validated by retrospective, industry-sponsored, or small series. METHODS: Tumor features, sentinel node biopsy (SNB) results, and outcomes were extracted from a prospective database of 383CM patients who underwent SNB and had a 31-GEP run on their primary tumor. Groups were compared by uni- and multi-variable analysis. Relapse-free and distant metastasis-free survival (RFS, DMFS) were estimated by Kaplan-Meier method. RESULTS: Breslow thickness, T stage, and SNB positivity were significantly higher in Class 2 patients. Recurrence rates were higher for Class 2 vs Class 1 patients and highest in patients who were Class 2 and SNB positive. GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC "low risk" (stages IA-IIA) patients. CONCLUSIONS: 31-GEP adds prognostic information in CM patents undergoing SNB.

published proceedings

  • Am J Surg

altmetric score

  • 1

author list (cited authors)

  • Arnot, S. P., Han, G., Fortino, J., Han, D., Fowler, G., & Vetto, J. T.

citation count

  • 5

complete list of authors

  • Arnot, Samuel P||Han, Gang||Fortino, Jeanine||Han, Dale||Fowler, Graham||Vetto, John T

publication date

  • June 2021